Τετάρτη 26 Μαΐου 2021

Intermediate-risk thyroid carcinoma: indicators of a poor prognosis

xlomafota13 shared this article with you from Inoreader

pubmed-meta-image.png

Arch Endocrinol Metab. 2021 May 18;64(6):764-771. doi: 10.20945/2359-3997000000290.

ABSTRACT

OBJECTIVE: The intermediate-risk (IR) category includes tumors with different degrees of aggression. We aimed to identify the risk factors associated with unfavorable response to initial treatment and compare the effect of low/high radioactive iodine (RAI) therapy.

METHODS: A total of 614 IR patients were selected from a database, during 1972-2015. All patients underwent total thyroid ectomy and RAI therapy and were reclassified after 12-18 months into the favorable (complete/indeterminate) response group and the unfavorable (biochemical/incomplete structural) response group. A total of 92 patients were assessed for late response (mean: 9.19 ± 5.73 years). Age, gender, tumor size, histology, multifocality, vascular invasion, extrathyroidal extension, presence and number of lymph node metastasis, and stimulated thyroglobulin at ablation (sTg) were evaluated.

RESULTS: Mean age at diagnosis was 41.47 ± 15.81 years, and 83.6% of the patients were female. Within 12-18 months after initial therapy, unfavorable response was detected in 41.2% of the patients and was associated, in multivariate analysis, with lymph node metastasis (p = 0.041; odds ratio [OR] = 1.9), presence of more than five metastatic lymph nodes (p = 0,017; OR = 2.6), and sTg > 10 ng/mL (p = 0.005; OR = 10.0). For patients with a longer follow-up, sTg >10 ng/mL was associated with unfavor able response (p = 0.002; OR = 6.8). A higher RAI dose was not related to better prognosis at the end of the follow-up.

CONCLUSION: A sTg level of >10 ng/mL and lymph node metastasis were associated with an unfavorable response 12-18 months after initial treatment. A RAI dose below 150 mCi was proven sufficient to treat IR patients.

PMID:34033287 | DOI:10.20945/2359-3997000000290

View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου